

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 1509)**

## **CLARIFICATION ANNOUNCEMENT REGARDING CERTAIN MEDIA REPORTS**

This announcement is published on a voluntary basis by Harmonicare Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”).

The Company pays high attention to the fact that recently certain media reported (the “**Media Reports**”) that the Medical Ethics Committee of Shenzhen HarMoniCare Gynecology and Paediatrics Hospital Co., Ltd. (深圳和美婦兒科醫院有限公司) (“**Shenzhen HarMoniCare Hospital 深圳和美醫院**”), a subsidiary of the Company, was involved in giving approval to a clinical project (the “**Claimed Project**”) led by He Jiankui (賀建奎) allegedly having used the CRISPR-Cas9 technology in embryo gene editing and having successfully led to the birth of the first gene-edited twin babies in November 2018 in the People’s Republic of China (“**China**”).

The Company hereby makes following statements and clarifications to prevent the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company from being misled:

1. Shenzhen HarMoniCare Hospital is a specialized hospital for women and children, the establishment of which was approved by the Health and Family Planning Commission of Shenzhen Municipality. It provides medical services in strict accordance with the requirements of the Health and Family Planning Commission of Shenzhen Municipality and the relevant laws and regulations and it is firmly opposed to conducting genetic experiments that violate human ethics and trespass the boundaries of humanity;
2. Shenzhen HarMoniCare Hospital has never participated in any clinical operation relating to the “gene-edited babies” incident mentioned by He Jiankui and his team on the internet, and the babies mentioned in the incident were not delivered in Shenzhen HarMoniCare Hospital;

3. Upon preliminary investigations by the Company, the signatures on the Application Form for Review by the Medical Ethics Committee of Shenzhen HarMoniCare Hospital (《深圳和美婦兒科醫院醫學倫理委員會審查申請書》) circulated on the internet are suspected to have been forged, and no relevant meeting of the Medical Ethics Committee of the hospital in fact took place. Shenzhen HarMoniCare Hospital will invite public-security organizations to participate in the investigations and pursue the legal responsibilities of the relevant individuals;
4. Shenzhen HarMoniCare Hospital will always strictly comply with the laws and regulations of China, the management standards of the Medical Ethics Committee, and carry out the relevant medical services in compliance of the foregoing;
5. The Group attaches great importance to this matter, and has set up a special investigation team to cooperate with the regulatory authorities on health and hygiene of China to conduct a thorough investigation of the incident and will make the investigation results available to the public as soon as possible; and
6. The Company does not condone the means of the Claimed Project, and has reservations as to the accuracy, reliability and truthfulness of its contents and results. The Company has not independently verified the Claimed Project and the Media Reports.

The Company has been upholding high standards of corporate governance, risk management and compliance at all times to protect the interests of its Shareholders, create greater value for the Shareholders as a whole and actively expand its business. The Company wishes to remind all Shareholders and potential investors of the Company to refer to the announcements published on the website of the Main Board of The Stock Exchange of Hong Kong Limited (<http://www.hkexnews.hk/index.htm>) and the website of the Company ([www.hemeiyl.com](http://www.hemeiyl.com)) when seeking information relating to the Company.

## **Information on Shenzhen HarMoniCare Hospital**

Shenzhen HarMoniCare Gynecology and Paediatrics Hospital Co., Ltd. (深圳和美婦兒科醫院有限公司), previously known as “Shenzhen HarMoniCare Gynecology Hospital Co., Ltd. (深圳和美婦科醫院)” is a limited liability company established in China and is a subsidiary of the Company owned by it as to 92% as at the date of this announcement. It is principally engaged in the provision of specialized gynecology and obstetrics medical services.

By Order of the Board  
**Harmonicare Medical Holdings Limited**  
**Lin Yuming**  
*Chairman, Executive Director and President*

Hong Kong, 27 November 2018

*As at the date of this announcement, the executive Directors are Mr. Lin Yuming, Mr. Fang Zhifeng and Mr. Zhao Xingli; the non-executive Directors are Mr. Lin Yuguo, Mr. Qiu Jianwei and Mr. Xu Jun; and the independent non-executive Directors are Mr. Kong Aiguo, Ms. Fang Lan and Mr. Cai Jiangnan.*